CaPRis study: Cannabis, potential and risks – Federal Ministry of Health

Insights into the recreational and medical use of cannabis. We take a look at the results of the study to find out more about the risks and opportunities associated with cannabis. The CaPRis study sheds light on the prevalence, the health consequences of recreational use and the therapeutic potential of cannabis for various diseases – and provides valuable insights into the current study situation. Back to overview: Cannabis studies.

CaPRis study: background and data

The CaPRis study (Cannabis: Potential and Risks) analyzes the effects and risks of cannabis use both recreationally and medically. The research was conducted by Dr. Eva Hoch(LMU Munich) and Dr. Miriam Schneider(University of Heidelberg) and supported by over 30 scientists. In total, more than 2,000 studies were analyzed.

Recreational use: prevalence, effects and consumption
  1. Distribution
  2. Mode of action and acute effects
  3. Chronic consumption
  4. Organic consequences
  5. Psychosocial consequences

Distribution

Cannabis is the most commonly consumed illegal drug in the EU, especially among adolescents and young adults.

In Germany, around 6.1% of the population between the ages of 18 and 64 use cannabis.

Mode of action and acute effects

THC, the main active ingredient, affects the central nervous system and can cause euphoria as well as memory and attention problems. The effect is temporary, but cannabis impairs the ability to drive.

Chronic consumption

Long-term use can impair the brain and cognitive abilities, with an increased risk of mental disorders such as psychosis and bipolar disorder.

Around 9% of consumers develop an addiction.

Organic consequences

Cannabis increases the risk of respiratory diseases. The link with cancer is unclear, with the exception of an increased risk of testicular cancer.

Psychosocial consequences

Frequent consumption can have a negative impact on educational success and lead to social problems.

Medical application

Cannabis has been approved for certain medical indications in Germany since 2017:

  1. Good evidence base
  2. Moderate evidence:
  3. Low level of evidence:

PS: What does evidence mean?

Evidence base refers to the availability and quality of scientific evidence for the effectiveness of a treatment or measure.

Good evidence base

Cannabis shows efficacy in chronic pain, especially neuropathic pain and multiple sclerosis.

Moderate evidence base

It helps with nausea and loss of appetite, especially in chemotherapy and HIV/AIDS patients.

Low level of evidence

Initial positive results have been seen in mental disorders and treatment-resistant epilepsies, but more studies are needed.

Side effects

THC-containing drugs can cause dizziness, sedation and nausea, while cannabidiol (CBD) is considered better tolerated. Serious side effects are rare.

Conclusion: What does the study say?

Cannabis poses clear health risks, especially for young people. Education and prevention are crucial, while synthetic cannabinoids pose particular dangers. Medical cannabis has potential, but studies are often still lacking for many areas of application.

The study highlights the need for further research to fully understand the multiple effects and therapeutic potential of cannabis.

Cannabis studies: Current

Up-to-date knowledge! In Germany, around 6.1% of the population between the ages of 18 and 64 use cannabis. What’s new? Read the latest news here:

 

Häufig von anderen gelesen